This A-1155463-Blast Makes The Whole CB-5083 Concept So Thrilling

All NAs belong to the same class (HBV polymerase inhibitors) and can be subdivided into nucleoside analogues including lamivudine (LAM), http://www.selleckchem.com/products/a-1155463.html ETV, telbivudine (TBV) and nucleotide analogues including adefovir dipivoxil (ADV) and TDF [3-5]. However, given the high potency and low resistance rates, only third generation NAs, i.e. ETV or TDF, should be considered as first-line drugs in patients with CHB. LAM, ADV and TBV are no longer recommended because of the limited efficacy and moderate to high resistance rates of these drugs [3-5]. This article reviews the long-term efficacy and safety of ETV and TDF in NAs-na?ve HBeAg-negative CHB patients. In the VIRGIL Study, including 243 NAs-na?ve CHB patients (mean age 43?years old, 24% with cirrhosis, 64% HBeAg-negative) treated with ETV monotherapy, the cumulative probability of achieving a sustained virological response (HBV DNA http://www.selleckchem.com/products/cb-5083.html patients at weeks 48, 96 and 144 was 89, 98 and 99%, respectively, with two patients (1%) who achieved HBsAg loss and none who developed ETV-resistance [7]. A United States study in 153 patients treated with ETV showed high response rates in na?ve HBeAg-negative patients that reached 100% at year 3 [8]. In a Hong Kong cohort including 132 NAs-na?ve HBeAg-negative patients receiving ETV, HBV DNA undetectability ( http://www.selleck.cn/products/PD-0332991.html cirrhosis, 83% HBeAg-negative) treated with ETV for 5?years, the rates of viral suppression and ALT normalization was 100 and 93% among HBeAg-negative patients respectively. One patient (0.7%) who developed ETV resistance at year 3, was successfully rescued by TDF [11]. The efficacy was similar after 1?year of treatment with ETV in decompensated and compensated patients with cirrhosis; patients achieved undetectable serum HBV DNA in 89% (decompensated cirrhosis) and 78% (compensated cirrhosis) respectively [12]. In a randomized, open-label study in 195 CHB patients with decompensated cirrhosis (45% HBeAg-negative), ETV 1?mg/die suppressed viral replication at week 48 more effectively than ADV 10?mg/die (57% vs 20%, P?